Madrigal Pharmaceuticals Inc. Common Stock (MDGL) fair value

ACCE thesis

Madrigal sells Rezdiffra (resmetirom), the first FDA-approved oral therapy for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with no other approved pill. The moat is regulatory and clinical: it is first to market in a large indication, and the product carries a 91.5% gross margin, so incremental sales drop almost straight to the bottom line once operating costs are covered. Revenue is growing 71.2% year on year, and the question for the next few quarters is how fast patients on the drug convert from early launch into sustained prescribing as payers and hepatologists build familiarity. The stock looks expensive on earnings, with a forward P/E of 78.1 against an operating margin of -15.5%, and return on equity of -53.3% shows the business is still spending well ahead of its profits. That profile makes it a name for a deeper look at the launch curve, reimbursement terms and cash runway, not a conclusion on valuation. Its composite score of 40/100 and absence from any index argue for caution on sizing until the margin trajectory is clearer.